1. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study. Issue 14 (4th May 2020) Authors: Seiwert, Tanguy Y.; Kochanny, Sara; Wood, Kevin; Worden, Francis P.; Adkins, Douglas; Wade, James L.; Sleckman, Bethany G.; Anderson, Daniel; Brisson, Ryan J.; Karrison, Theodore; Stadler, Walter M.; Vokes, Everett E. Journal: Cancer Issue: Volume 126:Issue 14(2020) Page Start: 3237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗